Phase 2 Peripheral Neuropathy Trial, Recruiting (NCT06915662)

Phase 2 Peripheral Neuropathy Trial, Recruiting NCT06915662 Sponsor: Massachusetts General Hospital Condition: Peripheral Neuropathy

Printed from Voxsanity (voxsanity.com.au) — NCT06915662 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Neuropathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are having traumatic amputation of one or more fingers or toes treated at MGB (Massachusetts General Brigham)
People who speak English

Who may not be able to join:

People who are having a planned revision amputation or an amputation that is not the result of a traumatic injury
People who are under 22 years old
People who are pregnant and/or breastfeeding
People who are unable or unwilling to take part in a research trial
People who have a known allergy to polyethylene glycol (PEG), or to the dyes FD&C Yellow No. 5 (also called tartrazine) or FD&C Blue No. 1 (also called brilliant blue FCF)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: (617) 726 - 4700

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06915662

Sponsor: Massachusetts General Hospital

Phase: Phase 2

Status: Recruiting

Condition: Peripheral Neuropathy

Trial contact: (617) 726 - 4700

More information: https://clinicaltrials.gov/study/NCT06915662

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are having traumatic amputation of one or more fingers or toes treated at MGB (Massachusetts General Brigham)
People who speak English

Who may not be able to join:

People who are having a planned revision amputation or an amputation that is not the result of a traumatic injury
People who are under 22 years old
People who are pregnant and/or breastfeeding
People who are unable or unwilling to take part in a research trial
People who have a known allergy to polyethylene glycol (PEG), or to the dyes FD&C Yellow No. 5 (also called tartrazine) or FD&C Blue No. 1 (also called brilliant blue FCF)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Massachusetts General Hospital

Registry

ClinicalTrials.gov

Start date

20 September 2025

Est. completion

1 April 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Visual Analog / Numerical Rating Scale (VAS/NRS) Scores); • Patient-Reported Outcomes Measurement Information System Pain Interference (PROMIS PI); Cold Intolerance Symptom Severity score (CISS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov